Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Remicade Market Size Forecast: How Big Could The Market Get By 2030?
The remicade market has shown robust expansion over recent years. This market is projected to expand, reaching $2803.31 million in 2026 from $2656.87 million in 2025, exhibiting a compound annual growth rate (CAGR) of 5.5%. Key contributors to its historical growth include the growing prevalence of autoimmune disorders, a broader clinical embrace of biologics, the expansion of hospital infusion centers, refined diagnostic methods for inflammatory diseases, and the development of specialty pharmaceutical distribution.
The remicade market is projected to experience substantial expansion over the coming years. It is anticipated to reach a valuation of $3433.68 million by 2030, exhibiting a compound annual growth rate (CAGR) of 5.2%. This anticipated growth during the forecast period is propelled by factors such as a surging demand for biosimilar products, escalating investments in the production of biologics, the broadening availability of home infusion care services, a heightened emphasis on customized autoimmune treatments, and significant progress in the development of monoclonal antibodies. Key developments defining this period encompass a rise in the application of TNF-alpha inhibitor therapies, increased acceptance of biologic interventions for autoimmune conditions, a growing inclination towards medications offering sustained disease management, the proliferation of specialized infusion offerings, and a sharpened focus on treatment results that prioritize the patient.
Get A Free Sample Report With In-Depth Market Insights:
Remicade Market Expansion Drivers: What’s Shaping Future Growth?
The remicade market is anticipated to expand due to the increasing occurrence of autoimmune diseases. These are disorders where the body’s immune system erroneously targets its own healthy cells, tissues, or organs, treating them as foreign invaders. The surge in autoimmune disease cases stems from factors such as genetic susceptibility, shifts in the environment, greater exposure to contaminants, lifestyle choices, and enhanced diagnostic capabilities. Remicade (infliximab) addresses autoimmune conditions by specifically inhibiting tumor necrosis factor-alpha (TNF-a), a crucial inflammatory protein implicated in diseases like rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. For example, data from April 2025 by GOV.UK, a UK government public health agency, indicated that in 2024, 17.9% of individuals aged 16 and above reported having a long-term musculoskeletal (MSK) condition. Among these, females showed a higher prevalence at 20.0% compared to males at 15.6%. Consequently, the growing frequency of autoimmune diseases is a primary driver for the remicade market.
Remicade Market Segment Analysis: What Are The Core Market Categories?
The remicade market covered in this report is segmented –
1) By Disease Indication: Crohn’s disease, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Ulcerative Colitis, Plaque psoriasis
2) By Route Of Administration: Subcutaneous, Intravenous, Parenteral
3) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
Remicade Market Strategic Trends: What Defines The Next Growth Phase?
Leading firms within the Remicade (infliximab) market are concentrating on creating novel solutions, notably subcutaneous versions of biologic treatments, to address the growing need for enhanced patient ease, better adherence to treatment, and more time-saving options compared to conventional intravenous administration. Subcutaneous biologics enable patients to manage their maintenance doses independently from home, thereby lessening the frequency of visits to infusion centers and offering a more readily available choice over typical IV formulations. An example of this trend occurred in March 2024, when Celltrion USA, Inc., a US biopharmaceutical firm, introduced Zymfentra (infliximab-dyyb), which is the initial FDA-approved subcutaneous infliximab formulation. Zymfentra is prescribed for ongoing treatment in adults experiencing moderate-to-severe active ulcerative colitis (UC) and Crohn’s disease (CD), conditions jointly referred to as inflammatory bowel disease (IBD). Following its approval for use after initial IV induction with an infliximab product, it presents a practical, self-administered option for extended disease management.
Remicade Market Top Companies Driving Competitive Growth
Major companies operating in the remicade market are Janssen Biotech Inc.
View The Full Remicade Market Report:
Remicade Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the remicade market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the remicade market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
